Long‐term safety of vedolizumab for inflammatory bowel disease

BACKGROUND: Vedolizumab, a gut‐selective α(4)β(7) integrin antibody, is approved for moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). AIM: To report the final results from the vedolizumab GEMINI long‐term safety (LTS) study. METHODS: The phase 3, open‐label GEMINI...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Aliment Pharmacol Ther
Asıl Yazarlar: Loftus, Edward V., Feagan, Brian G., Panaccione, Remo, Colombel, Jean‐Frédéric, Sandborn, William J., Sands, Bruce E., Danese, Silvio, D’Haens, Geert, Rubin, David T., Shafran, Ira, Parfionovas, Andrejus, Rogers, Raquel, Lirio, Richard A., Vermeire, Séverine
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2020
Konular:
Efficacy and Safety of Biologics for Crohn's Disease
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540482/
https://ncbi.nlm.nih.gov/pubmed/32876349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.16060
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller